secwatch.observer — SEC 8-K summary
======================================

Issuer:     Acumen Pharmaceuticals, Inc. (ABOS)
CIK:        0001576885
Form:       8-K
Filed at:   2025-11-12T23:59:59+00:00
Accession:  0001576885-25-000102
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Acumen reports Q3 net loss $26.5M; cash $136.1M supports ops into early 2027
----------------------------------------------------------------------------

- Cash, equivalents & marketable securities $136.1M at Sept 30, down from $166.2M at June 30; runway into early 2027.
- Net loss $26.5M vs $29.8M YoY; R&D expense fell to $22.0M from $27.2M.
- First patient dosed in November 2025 in open-label extension of Phase 2 ALTITUDE-AD trial of sabirnetug.
- Expect non-clinical data for EBD candidate in early 2026; Phase 2 topline results in late 2026.
- Added biopharma veteran George Golumbeski as Chairman, board expanded to 8 members.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1576885/000157688525000102/0001576885-25-000102-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1576885/000157688525000102/abos-20251112.htm
  HTML page:      https://secwatch.observer/filing/0001576885-25-000102

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer